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Epstein-Barr virus (EBV) infection converts resting human B cells into permanently prolifer-
ating lymphoblastoid cell lines (LCLs). The Epstein-Barr virus nuclear antigen 2 (EBNA2)
plays a key role in this process. It preferentially binds to B cell enhancers and establishes a
specific viral and cellular gene expression program in LCLs. The cellular DNA binding factor
CBF1/CSL serves as a sequence specific chromatin anchor for EBNA2. The ubiquitous
expression of this highly conserved protein raises the question whether additional cellular
factors might determine EBNA2 chromatin binding selectively in B cells. Here we used
CBF1 deficient B cells to identify cellular genes up or downregulated by EBNA2 as well as
CBF1 independent EBNA2 chromatin binding sites. Apparently, CBF1 independent EBNA2
target genes and chromatin binding sites can be identified but are less frequent than CBF1
dependent EBNA2 functions. CBF1 independent EBNA2 binding sites are highly enriched
for EBF1 binding motifs. We show that EBNA2 binds to EBF1 via its N-terminal domain.
CBF1 proficient and deficient B cells require EBF1 to bind to CBF1 independent binding
sites. Our results identify EBF1 as a co-factor of EBNA2 which conveys B cell specificity to
EBNA2.
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Epstein-Barr virus (EBV) infection is closely linked to cancer development. At particular
risk are immunocompromised individuals like post-transplant patients which can develop
B cell lymphomas. In healthy individuals EBV preferentially infects B cells and establishes
a latent infection without causing apparent clinical symptoms in most cases. Upon infec-
tion, Epstein-Barr virus nuclear antigen 2 (EBNA2) initiates a B cell specific gene expres-
sion program that causes activation and proliferation of the infected cells. EBNA2 is a
transcription factor well known to use a cellular protein, CBF1/CSL, as a DNA adaptor.
CBF1/CSL is a sequence specific DNA binding protein robustly expressed in all tissues.
Here we show that EBNA2 can form complexes with early B cell factor 1 (EBF1), a B cell
specific DNA binding transcription factor, and EBF1 stabilizes EBNA2 chromatin bind-
ing. This EBNA2/EBF1 complex might serve as a novel target to develop future small mol-
ecule strategies that act as antivirals in latent B cell infection.
Introduction
CBF1/CSL (C promoter binding factor, Suppressor of Hairless, and lag1 also called RBPJ or
RBPJκ) is a cellular DNA binding protein, ubiquitously expressed in all mammalian tissues.
CBF1 serves as a DNA adaptor molecule that recruits either repressors or activators to tran-
scriptional control elements like enhancers and transcription start sites of genes and is
described as the major downstream effector of the cellular Notch signal transduction pathway
[1]. Notch signaling controls the development and differentiation of diverse organs and tis-
sues. Despite the ubiquitous expression of its chromatin anchor CBF1, target gene control by
Notch is context dependent and requires tissue and lineage specific cooperating transcription
factors [2]. In B cells, latently infected with Epstein-Barr virus (EBV), CBF1 anchors the viral
transactivator protein EBV nuclear antigen 2 (EBNA2) to chromatin and thereby initiates a
cascade of signaling events that coordinate B cell activation and proliferation of infected cells
[3–6]. Thus, EBNA2 is considered to mimic Notch signaling [7]. In contrast to the universal
expression and pleiotropic activities of Notch, the expression and the biological activity of
EBNA2 is strictly confined to EBV infected B cells, characterized by a transcription program
that phenocopies antigen activated B cell blasts [8, 9].
CBF1 and EBNA2 frequently co-occupy cellular enhancer and super-enhancer regions
reinforcing the concept that CBF1 is the major adaptor for EBNA2 to chromatin [10]. In addi-
tion, EBNA2 bound regions are co-occupied with multiple additional transcription factors
including IRF4, BATF, NFκB, Runx, and ETS family members as well as the B cell lineage
defining and pioneer factors PU.1/SPI1 and EBF1 [10, 11]. While the adaptor function of
CBF1 is well defined, a potential functional contribution of these co-occurring factors to
EBNA2 function has not been studied thoroughly. These proteins are active transcription fac-
tors which carry transactivation domains and can actively promote or impair transcription of
target genes. PU.1/SPI1 promotes B cell development and is expressed throughout B cell differ-
entiation, but also controls T cell, myeloid and dendritic cell differentiation [12]. PU.1/SPI1
DNA binding sites are critical for LMP1 promoter luciferase activation [3, 13–15]. However,
its contribution to LMP1 expression in the context of the entire viral genome is surprisingly
weak [16]. Most recently it has been shown that EBNA2 enhances the binding of CBF1 and
EBF1 to chromatin and EBF1 is critical for expression of the EBNA2 viral target gene LMP1
[16, 17]. By sequential chromatin immunoprecipitation, EBF1 and EBNA2 have been shown
to bind to the same chromatin fragment in the same cell [17]. Importantly, within the
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hematopoietic compartment EBF1 is exclusively expressed in B cells and their lymphocytic
precursors. The other EBF gene family members EBF2, 3, and 4 are expressed at very low or
undetectable levels in B cells. EBF1 initiates B cell lineage commitment, development and dif-
ferentiation as a pioneer factor that promotes chromatin accessibility and DNA demethylation
in lymphocyte precursors [18, 19].
Strong EBNA2 binding correlates with extended regions of extraordinarily high histone 3
lysine 27 acetylation (H3K27ac) and H3K4 mono-methylation (H3K4me1) marks which are
characteristic features of activated super enhancers [11]. In addition, EBNA2 modulates the
formation of chromatin loops to connect enhancers and promoters of its target genes [20]. In
theory, EBNA2 co-occurring factors, like PU.1/SPI1 and EBF1 could function as pioneer fac-
tors for EBNA2 by modulating the chromatin state and thereby promoting access of EBNA2 to
chromatin, indirectly. Alternatively, EBNA2 co-occurring factors might serve as alternate
adaptors that promote DNA binding of EBNA2.
CBF1 is ubiquitously expressed in all mammalian cells including primary human B cells
and EBV infected and non-infected human B cell lines. For this study, we used a CBF1 defi-
cient human B cell line, which had been generated by homologous recombination in the
somatic B cell line DG75, to screen for CBF1 independent functions of EBNA2. The parental
DG75 B cell line is an EBV negative Burkitt’s lymphoma cell line. While the knock-down of
EBF1 and CBF1 in EBV immortalized B cells severely impairs cellular viability [17], DG75 cells
tolerate inactivation of the CBF1 gene without loss of viability [21, 22]. We compared EBNA2
induced cellular genes in CBF1 proficient and deficient DG75 cells and found the majority of
EBNA2 target genes to be CBF1 dependent. A minor fraction of EBNA2 target genes is regu-
lated CBF1 independently. By chromatin immunoprecipitation and genome wide sequencing
of EBNA2 bound DNA fragments (ChIP-Seq), we identified a subpopulation of CBF1 inde-
pendent EBNA2 binding sites that was significantly enriched for EBF1 binding motifs. We
show that CBF1 independent EBNA2 binding to chromatin is dependent on EBF1 protein
expression. Importantly, we demonstrate that EBNA2 and EBF1 can form protein complexes
in CBF1 positive and negative cells, indicating that EBF1 serves as B cell specific DNA anchor
for EBNA2.
Results
Genome wide expression profiling identifies cellular transcripts regulated
by EBNA2 in CBF1 deficient B cells
In order to rigorously test if EBNA2 can exert any functions in the absence of its DNA adaptor
CBF1, a microarray based genome wide screen for EBNA2 target genes in DG75 B cells that
are either proficient (wt) or deficient (ko) for CBF1 was performed (Fig 1A, 1B and 1F and S1
Table). Both cell lines constitutively express an estrogen receptor (ER) hormone binding
domain EBNA2 fusion protein (ER/EBNA2). ER/EBNA2 is retained in the cytoplasm of the
cell but is rapidly activated and translocated to the nucleus in response to estrogen [21, 22].
For expression profiling, DG75ER/EBNA2 CBF1 wt and CBF1 ko cells were cultured in estrogen
supplemented media for 24 h, total cellular RNAs were harvested and processed for the hybrid-
ization of gene arrays that detect 30645 coding transcripts, 11086 lincRNAs (long intergenic
non-coding RNA transcripts) and 148 miRNAs (micro RNAs). Cell cultures of the parental
DG75 CBF1 wt and CBF1 ko cell lines, which do not express ER/EBNA2, were treated with
estrogen and processed for the microarray analysis as specificity controls. Neither in DG75
CBF1 wt nor in DG75 CBF1 ko cells statistically significant changes (p 0.05) of cellular tran-
script abundance in response to estrogen treatment were observed, proving that target gene
activation is strictly dependent on ER/EBNA2 (S1A Fig). In addition, estrogen responsive
EBF1, a cofactor of EBNA2
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Fig 1. Comparative transcript profiling of EBNA2 target gene expression in CBF1 proficient and deficient DG75 cells. DG75
cells expressing ER/EBNA2 were cultivated in estrogen supplemented medium for 24 h or were left untreated. Total cellular RNA was
isolated and submitted to gene expression analysis using the Human Gene 2.0 ST array. All probe sets represent single transcripts
(trxs). For each condition, 3 biological replicates were examined. Each vertical column represents the results obtained after hybridizing
a single microarray. Horizontal rows represent data obtained for a particular probe set across all cell lines and conditions adjusted to a
EBF1, a cofactor of EBNA2
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006664 October 2, 2017 4 / 30
target genes described in the literature did not change expression levels proving that the estro-
gen receptor response is not functional in DG75 B cells (S1B Fig) [23–27]. It is important to
note that EBNA2 not only activates a set of direct target genes but thereby initiates a cascade of
secondary events, which are included in our target gene lists and in total reflect EBNA2
functions.
Based on expression level changes of 950 transcripts ( 2-fold, p 0.05) which are regu-
lated in DG75ER/EBNA2 CBF1 wt and expression levels of the same transcripts in DG75ER/EBNA2
CBF1 ko cells 12 clusters of transcripts were defined and illustrate the complex patterns that
arise. Transcripts in cluster I, II, IV and VI are upregulated in CBF1 wt cells. Cluster VII tran-
scripts are upregulated in both, wt and ko cells. Cluster III transcripts are down-regulated in
CBF1 wt only, while cluster VIII transcripts are down-regulated in both, wt and ko cell (S2 Fig
and S2 Table). Multiple previously characterized EBNA2 target genes were significantly upre-
gulated in DG75ER/EBNA2 CBF1 wt cells (S1C Fig). In total, 99 cellular transcripts were up-
and 37 cellular transcripts were downregulated 4-fold (p 0.001) (Fig 1A). Importantly,
15 transcripts were upregulated and 6 transcripts were downregulated in CBF1 deficient
DG75ER/EBNA2 4-fold (Fig 1B). Although the number of differentially expressed EBNA2 tar-
get genes was markedly higher in CBF1 proficient cells, the mean changes of the response were
similar in CBF1 proficient and deficient cells as illustrated for genes regulated 2-fold
(p 0.05) (Fig 1C).
The majority of EBNA2 target genes identified in CBF1 deficient cells were also regulated
in CBF1 proficient cells, while a small group of targets is regulated by EBNA2 in CBF1 defi-
cient cells, only (ko only, Fig 1D and 1E). On average, the transcripts which are regulated in
CBF1 proficient and deficient cells (wt & ko) showed a stronger response than those regulated
in proficient cells, only (wt only). In order to verify the microarray results, a panel of 12 CBF1
dependent (S2 Fig cluster 2) and independent targets (S2 Fig cluster 7) was selected for re-test-
ing. RT-qPCR experiments confirmed that most CBF1 independent targets also responded to
EBNA2 in CBF1 proficient cells. As already seen in the microarray experiment, the degree to
which individual targets responded in CBF1 proficient cells varied considerably but was faith-
fully reproduced by RT-qPCR (S4 Fig). Interestingly, the CBF1 dependent target genes
included a substantial number of miRNAs that are up- or downregulated by EBNA2 (S5 Fig).
CBF1 independent EBNA2 repressed target genes are enriched for
genes involved in B cell signaling
To functionally characterize EBNA2 target genes, biological processes associated with individ-
ual subsets of genes were analyzed. The online tool GOrilla was used to test whether differen-
tially expressed genes in comparison to all other genes on the array were enriched in any of the
GO terms in the “Biological Process” category. The subsets considered here consisted of genes
that were on average induced or repressed in the CBF1 proficient and deficient cell lines, or
scale ranging from -2.0 to + 2.0. The relative high, medium and low expression values are represented by red, white and blue color,
respectively. Vertical columns are ranked according to fold changes from highest induction levels on top to highest repression levels at
the bottom. (A) Expression levels of 136 transcripts which change expression levels at least 4-fold (p 0.001) in response to EBNA2 in
CBF1 proficient DG75 (DG75ER/EBNA2 CBF1 wt) cells are displayed. The transcript cluster ID and the assigned genes/transcripts,
including non-coding RNAs, are annotated. (B) 21 transcripts regulated at least 4-fold (p 0.001) in CBF1 deficient DG75 (DG75ER/
EBNA2 CBF1 ko). (C) Boxplots depicting the fold change distribution of EBNA2 induced and repressed transcripts for the subset of target
genes changed at least 2-fold (p 0.05) in CBF1 wt and ko cells, respectively. EBNA2 induced (D) and repressed (E) transcripts are
shown to illustrate the dynamic range of each system. Boxplot whiskers extend to 1.5x interquartile range. Dotted lines mark the 2-fold
change chosen as cut-off. (F) Expression levels of EBNA2 (prior to and after estrogen treatment) and CBF1 proteins were monitored by
Western blot analysis. Equal amounts of total protein lysates were applied and GAPDH served as an internal loading control. One
representative experiment (n = 3) is shown.
https://doi.org/10.1371/journal.ppat.1006664.g001
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genes where induction or repression was dependent or independent of CBF1. Only genes sig-
nificantly (q< 0.01) regulated in at least one of the two cell lines were considered. Thresholds
on fold changes were chosen by the online tool GOrilla in a data dependent manner to identify
subsets enriched in GO terms in the “Biological Process” category (S6 Fig).
Neither genes repressed in CBF1 proficient cells only (repressed/CBF1 dependent) nor
induced in CBF1 deficient cells (induced/CBF1 independent) were significantly (q 10−4)
enriched for any biological process. Genes induced in CBF1 proficient cells only (induced/
CBF1 dependent) were strongly and most significantly enriched for immunoglobulin receptor
binding and moderately enriched for biological processes involving several enzymatic activities
(Table 1).
Target genes repressed by EBNA2 in the absence of CBF1 (repressed/ CBF1 independent)
showed a remarkable profile (Table 2). They map to several GO terms that cover diverse
immune responses. Since the study had been performed in B cells, the enrichment for genes
involved in immune responses and B cell receptor biology could have been expected. However,
our study indicates that EBNA2 also represses immune response genes and this feature of
EBNA2 is CBF1 independent.
EBNA2 is recruited to chromatin in CBF1 deficient B cells
In summary, our differential expression analysis of EBNA2 target genes shows that EBNA2
can regulate a small fraction of its target genes without using CBF1 as a DNA anchor. In order
to uncover alternative strategies of EBNA2 to bind to chromatin, we performed chromatin
immunoprecipitation (ChIP) studies to identify genomic loci that are bound by EBNA2 in
CBF1 negative cells. In ER/EBNA2 expressing cells, EBNA2 shuttles from the cytoplasm to the
nucleus in response to estrogen. In order to avoid a potential impact of cytoplasmic ER/
EBNA2 contamination on our biochemical studies, we switched to a doxycycline inducible
HA-EBNA2 expression system (doxHA-E2) in DG75 (S7A Fig). In the absence of doxycycline,
EBNA2 is not expressed and cannot interfere with the immunoprecipitation procedure in
DG75doxHA-E2/CBF1 wt and DG75doxHA-E2/CBF1 ko cells. Up to 90% of the cells express
EBNA2 when treated with doxycycline (S7B Fig). EBNA2 protein signal detected by immunos-
taining was 5- to10-fold stronger than EBNA2 in LCLs (S7C Fig). In comparison to LCLs,
Table 1. Gene ontology enrichment analysis of CBF1 dependent EBNA2 induced target genes.
Term ID* Term Genes in term Target genes in term** Enrichment Score*** q-value
GO:0034987 immunoglobulin receptor binding 19 10 58,08 5,59E-12
GO:0004252 serine-type endopeptidase activity 30 8 29,43 1,13E-06
GO:0008236 serine-type peptidase activity 33 8 26,75 2,16E-06
GO:0017171 serine hydrolase activity 33 8 26,75 1,80E-06
GO:0003823 antigen binding 49 11 24,77 5,03E-09
GO:0070011 peptidase activity, acting on L-amino acid peptides 137 8 15,39 1,14E-04
GO:0008233 peptidase activity 142 8 14,85 1,35E-04
GO:0004175 endopeptidase activity 84 12 12,79 1,25E-06
GO:0004872 receptor activity 226 33 2,61 6,65E-04
GO:0060089 molecular transducer activity 226 33 2,61 5,98E-04
*The top 10 GO terms in the “Biological Process” category are depicted. Note that a given gene can be annotated to multiple terms.
**number of genes in the top of the EBNA2 target gene list (chosen by GOrilla)
***Enrichment of a given GO term among differentially regulated genes with respect to the total number of genes assayed and annotated to them,
calculated by GOrilla, see Material and methods
https://doi.org/10.1371/journal.ppat.1006664.t001
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some of the EBNA2 co-occurring transcription factors like BATF and IRF4 were expressed at
very low levels while EBF1 and PU.1/SPI1 were robustly expressed (S7C Fig). ChIP followed
by high throughput sequencing (ChIP-seq) was performed to determine EBNA2 genome
occupancy. 1,789 EBNA2 binding sites were identified in CBF1 proficient DG75dox-HA2 (Fig
2A), while 22,500 EBNA2 peaks were identified in LCLs, which had been performed in paral-
lel. 1,325 (74%) of the EBNA2 peaks in DG75doxHA-E2 cells were also present in LCLs (shared
peaks), while 464 binding sites occurred exclusively in DG75doxHA-E2 cells. EBNA2 signal
intensity was most prominent at LCL/DG75doxHA-E2 shared EBNA2 binding sites (Fig 2B and
S8 Fig).
In LCLs, EBNA2 is preferentially recruited to enhancer elements which pre-exist in periph-
eral CD19 positive B cells before they are infected by EBV to generate LCLs [10]. Chromatin
marks characteristic for activated enhancer elements are H3K27ac in combination with
H3K4me1 signals that are stronger than H3K4me3. We speculated that DG75 specific chroma-
tin signatures in the absence of EBV infection might influence EBNA2 binding. We thus com-
pared H3K4me1, H3K4me3, and H3K27ac signal intensities at EBNA2 binding sites i) shared
by LCLs and DG75doxHA-E2, ii) unique for LCLs and iii) unique for DG75 in naïve CD19 posi-
tive B cells with those in non-transfected DG75.
EBNA2 binding sites, shared by LCLs and DG75doxHA-E2, stand out as the subset with the
most prominent enrichment for all three investigated histone modifications associated with
the chromatin state of active enhancers (Fig 2C). In contrast, DG75doxHA-E2 unique EBNA2
binding sites were highly enriched for active chromatin marks in the DG75 precursor only,
while LCL unique EBNA2 peaks showed significantly lower signal intensities in DG75. These
Table 2. Gene ontology enrichment analysis for CBF1 independent EBNA2 repressed target genes.
Term ID* Term Genes in term Target genes in
term**
Enrichment Score*** q-value
GO:0002768 immune response-reg. cell surface receptor signaling
pathway
46 27 3,52 1,09E-
06
GO:0002757 immune response-activating signal transduction 52 30 3,46 3,87E-
07
GO:0002764 immune response-reg. signaling pathway 54 31 3,44 3,08E-
07
GO:0050778 positive regulation of immune response 68 36 3,18 2,96E-
07
GO:0002429 immune response-act. cell surface receptor signaling
pathway
44 31 2,87 1,29E-
06
GO:0050776 regulation of immune response 84 39 2,79 1,25E-
06
GO:0002253 activation of immune response 54 36 2,72 8,67E-
07
GO:0002376 immune system process 149 56 2,26 1,16E-
06
GO:0007166 cell surface receptor signaling pathway 152 73 1,9 1,90E-
06
GO:0007165 signal transduction 311 128 1,59 6,01E-
07
*The top 10 GO terms in the “Biological Process” category are depicted. Note that a given gene can be annotated to multiple terms.
**number of genes in the top of the EBNA2 target gene list (chosen by GOrilla)
***Enrichment of a given GO term among differentially regulated genes with respect to the total number of genes assayed and annotated to them,
calculated by GOrilla, see Material and methods
https://doi.org/10.1371/journal.ppat.1006664.t002
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data indicate that a set of enhancers, which are pre-activated in DG75 cells but not in the
CD19 positive LCL precursors, might allow the formation of "DG75 unique" EBNA2 binding
sites. DG75 lack pre-formed enhancer signatures at "LCL unique" binding sites. ChIP signals
for CBF1 and EBF1 are most highly enriched at EBNA2 binding peaks shared by LCLs and
Fig 2. Cell line specific chromatin signatures predispose specific sites for EBNA2 binding. (A) Intersection of EBNA2 binding sites
identified in LCLs and DG75doxHA-E2 CBF1 wt cells. (B) Anchor plots showing EBNA2 ChIP-seq signal intensities for LCLs and for DG75doxHA-E2
CBF1 wt at sites identified in both cell lines (LCL/DG75doxHA-E2 shared) or unique to either cell line (LCL unique or DG75doxHA-E2 unique). (C)
ChIP-seq signals associated with active chromatin and enhancer state (H3K4me1, H3K4me3, and H3K27ac) at EBNA2 binding sites in CD19
+ B cells and DG75 cell line. Using ChIP-seq data provided by public resources [28, 29], the mean normalized signal for each histone
modification and peak subset was calculated for the region flanking all EBNA2 peak centers for 20 kb in each direction, applying the same
workflow for CD19+ B cells and DG75 data sets. Please note that absolute values of signal intensities for the same histone modification should
not be compared between the two cell lines since the experiments were conducted by different laboratories using different antibodies. (D) ChIP-
seq signals for CBF1, EBF1, BATF and IRF4 at LCL/DG75doxHA-E2 shared or LCL unique or DG75doxHA-E2 EBNA2 binding peaks.
https://doi.org/10.1371/journal.ppat.1006664.g002
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DG75doxHA-E2, while enrichment at LCL unique peaks was attenuated. In contrast, BATF and
IRF4 were strongly enriched at shared LCLs and DG75doxHA-E2as well as LCL unique peaks.
Thus, low abundance of IRF4 and BATF proteins or other co-occurring transcription factors
in DG75doxHA-E2 might limit EBNA2 occupancy in DG75 at these LCL unique sites.
The comparison of ChIP-Seq data between DG75doxHA-E2 CBF1 wt and ko cells identified
1,789 EBNA2 binding sites in CBF1 proficient and 271 in CBF1 deficient DG75. 243 (81%)
were found in both cell lines and thus constitute CBF1 independent EBNA2 peaks (Fig 3A).
The majority of EBNA2 binding sites found in CBF1 proficient (74%) and deficient (83%)
DG75 were shared with LCLs (S8 Fig). A small group of 28 binding sites were only identified
in CBF1 deficient cells and were not analyzed further. 1,546 EBNA2 sites were not detected in
CBF1 deficient cells and thus defined as "CBF1 dependent". The mean EBNA2 signal intensity
at EBNA2 binding sites was elevated 1.4-fold in wt compared to ko cells (Fig 3B and 3C).
Remarkably, EBNA2 binding to CBF1 independent peaks was significantly enriched compared
to CBF1 dependent peaks in CBF1 wt cells (2.5-fold, Fig 3D and 3E). The quantitative re-anal-
ysis of the subclasses of EBNA2 peaks in LCLs confirmed that CBF1 independent peaks are
characterized by stronger EBNA2 enrichment (Fig 3D, 3E and 3F, right panel). Since CBF1
independent EBNA2 binding obviously contributes to EBNA2 occupancy in LCLs, we con-
clude that our CBF1 deficient B cell line is a valid model system to study mechanisms which
drive EBNA2 chromatin interactions.
To better characterize CBF1 dependent and independent EBNA2 binding sites prior to
EBNA2 binding we could use H3K4me1, H3K4me3, and H3K27ac ChIP-Seq data published
for DG75 [29]. Signal intensities of H3K4me1, H3K4me3, and H3K27ac were reanalyzed sepa-
rately plotted for the CBF1 dependent and independent peak subpopulations and compared to
the mean signal peak intensities of the respective chromatin modification in DG75 (Fig 4). All
three activation marks showed almost the same high enrichment profiles for both subpopula-
tions indicating that chromatin signatures are most probably not the trigger either for CBF1
dependent or independent binding.
CBF1 independent EBNA2 peaks are significantly enriched for EBF1
binding motifs and EBF1 signal intensities in LCLs
To further investigate CBF1 independent EBNA2 binding to chromatin, de novo motif enrich-
ment analyses of the two subclasses of EBNA2 binding sites were performed separately. Strik-
ingly, the motif of EBF1, an important player in B cell development, was identified as the only
and also highly enriched TF motif in the CBF1 independent EBNA2 peak subset, while CBF1
and EBF1 motifs as well as a CBF1/EBF1 composite core motif, show up in the top five motifs
of the CBF1 dependent EBNA2 peak set (Fig 5A). In order to look at peak sets of similar size,
243 out of 1546 CBF1 dependent peaks were randomly selected and re-analyzed. For this
reduced set, only the CBF1 and EBF1 motifs were significantly enriched. Since the majority of
EBNA2 binding sites are also present in LCLs, we could use publicly available ChIP-seq data
for EBF1 in LCLs to investigate EBF1 enrichment at CBF1 independent compared to depen-
dent sites (Fig 5B, 5C and S8 Fig). Average CBF1 signal enrichment at EBNA2 binding sites
did not significantly differ between CBF1 independent and dependent sites. However, the
EBF1 signal was highly and significantly enriched at CBF1 independent compared to CBF1
dependent sites, indicating a potential role for EBF1 in mediating CBF1 independent EBNA2
binding to chromatin. Further quantitative correlation analyses focusing on signal intensities
of EBNA2, CBF1, EBF1, and PU.1/SPI1 (Fig 5D and 5E) were performed to rank these co-
occurring factors in a quantitative manner. PU.1/SPI1 was included since it had been sug-
gested to serve as a DNA anchor for EBNA2 in the past. As expected, CBF1 showed the highest
EBF1, a cofactor of EBNA2
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006664 October 2, 2017 9 / 30
Fig 3. EBNA2 can access more than 15% of its chromatin binding sites in CBF1 deficient DG75 B cells.
(A) Intersection of EBNA2 binding sites identified in CBF1 proficient or deficient cells 24 h post doxycycline
induction. 1,546 peaks that were identified in CBF1 proficient but not in CBF1 deficient cells were defined as
"CBF1 dependent" EBNA2 peaks. 243 EBNA2 peaks identified in CBF1 deficient and proficient DG75 cells were
defined as "CBF1 independent". (B-E) Comparison of EBNA2 ChIP-seq signal distributions at CBF1
independent or dependent peaks. (B) Anchor and (C) scatter plots (mean + 95% CI) depicting ChIP-seq signal
distributions at EBNA2 peak subsets. Regions flanking the peak center for 2 kb in each direction were analyzed
(Data underlying panel B). Absolute means and SEMs are indicated below. (D) Anchor and (E) scatter plots
(mean + 95% CI) as shown in B and C but depicting EBNA2 ChIP-seq signal intensities for the two different
subsets of EBNA2 peaks as defined in A. Statistical significance for differences of all means were assessed
applying unpaired two-tailed t-test for log values with Welch’s correction (**** p < 0.0001); absolute means and
SEMs are indicated below. (F) List of EBNA2 mean ChIP-seq signal intensities at CBF1 independent and
dependent peaks.
https://doi.org/10.1371/journal.ppat.1006664.g003
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correlation in signal distribution with EBNA2 at EBNA2 peaks (rs = 0.46) as well as genome
wide (rs = 0.5). Most strikingly, EBF1 highly correlated with EBNA2 signals at EBNA2 peaks
(rs = 0.4) as well as genome wide (rs = 0.42). However, PU.1/SPI1 and EBNA2 signal intensities
correlated weakly at EBNA2 peaks (rs = 0.19) as well as genome wide (rs = 0.17).
The N-terminal EBNA2 (END) domain of EBNA2 is sufficient to bind
EBF1
To test, if EBF1 can bind EBNA2, we performed co-immunoprecipitation (Co-IP) studies in
DG75doxHA-E2 CBF1 wt and ko cells. After ectopic expression of EBF1 in DG75, an EBF
Fig 4. CBF1 independent and dependent EBNA2 binding sites are significantly enriched for activated
chromatin marks in DG75 cells prior to EBNA2 binding. Based on published data sets on histone
modification in DG75, the two EBNA2 peak subsets (CBF1 independent dark blue; CBF1 dependent light blue)
were separately analyzed for histone activation marks typically found at enhancer regions. These data were
compared to signal intensities of all peaks for the respective chromatin modification (red). (A) Anchor plots
depict H3K4me1, H3K4me3, and H3K27ac at the respective peak centers and 20 kb flanking regions. (B) Data
underlying panel (A) were used to generate boxplots showing the signal distributions encompassing the entire
40 kb genomic region. The significance of differences of means was assessed by unpaired two-tailed t-tests
with Welch’s correction (**** p < 0.0001, *** p < 0.001). The differences of means for CBF1 independent
compared to CBF1 dependent EBNA2 peaks for H3K4me1 (-0.3004 ± 0.7957; p = 0.706), H3K4me3
(0.4323 ± 1.411; p = 0.7595), and H3K27ac (-0.5184 ± 0.3501: p = 0.1396) were not statistically significant.
Box plot whiskers extend to 1.5x interquartile range. (C) Table summarizing means and SEMs of histone
modifications analyzed in (A) and (B).
https://doi.org/10.1371/journal.ppat.1006664.g004
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Fig 5. The EBF1 binding motif is highly enriched at CBF1 independent binding sites and the EBF1 signal correlates with EBNA2
binding signal distributions. (A) De novo identified DNA sequence motifs and the respective E-values at CBF1 independent and dependent
EBNA2 binding sites as discovered by MEME-ChIP [30]. The analysis was performed for different sized data sets. TFs predicted to recognize the
respective motifs, as assigned by TOMTOM (using the hocomoco v10 data base), are listed. If multiple TFs with comparable significances were
assigned to one motif, the motif was designated as “core motif” for this subset. (B) CBF1 independent (dark blue) and dependent (light blue)
EBNA2 binding sites were compared for CBF1 and EBF1 enrichment in LCLs. The average signal intensities for all EBF1 and all CBF1 peaks in
LCLs are shown as reference for comparison (green), respectively. (C) The underlying data of panel B was used to generate box plots depicting
signal distributions. An unpaired two-tailed t-test with Welch’s correction (**** p < 0.0001) was performed to determine significant differences
between means. Box plot whiskers extend to 1.5x interquartile range. (D) Scatter plots of CBF1, PU.1, and EBF1 versus EBNA2 signal intensities
for EBNA2 peaks in LCLs. For each transcription factor the maximal signal intensity was set to 1 to plot signal intensities as relative signal. Each
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specific antibody co-immunoprecipitated EBNA2 from cellular extracts in both CBF1 profi-
cient as well as CBF1 deficient cells. This indicates that, CBF1 is not required for complex for-
mation of EBF1 with EBNA2 (Fig 6A). The interaction of EBNA2 and CBF1 is well
characterized. Two tryptophan residues (WW) within conserved region 6 are absolutely criti-
cal for EBNA2 to bind to CBF1 [4]. In order to test, whether the same region might also confer
EBF1 binding, we generated DG75 cells expressing an EBNA2 WW325FF mutant (DG75dox-
HA-E2-WW). EBF1 was readily co-precipitated with EBNA2 WW325FF suggesting that EBF1
and CBF1 might target different regions of EBNA2 (Fig 6B).
The N-terminal region of EBNA2, comprising residues 1–58, appears to mediate multiple
molecular functions including self-association and transactivation [31, 32]. We have recently
described the three-dimensional structure of the EBNA-2 N-terminal dimerization (END)
domain by heteronuclear NMR-spectroscopy. The END domain monomer comprises a small
fold of four β-strands and an α-helix which form a parallel dimer by interaction of two β-
strands from each protomer [33]. To further delineate the EBNA2 region that mediates the
interaction with EBF1, we expressed glutathione S-transferase (GST) -END domain fusion
proteins in bacteria and used the purified recombinant GST-END proteins as baits to affinity
capture EBF1. GST-END specifically pulled down EBF1 in EBF1 transfected cells proving that
the N-terminal domain of EBNA2 is sufficient to bind to EBF1 (Fig 6C).
EBF1 recruits EBNA2 to CBF1 independent binding sites
Since CBF1 was neither required nor inhibitory for EBF1/EBNA2 complex formation, we
asked if EBNA2 needs EBF1 to bind to either CBF1 independent or dependent chromatin
sites. To this end, EBF1 protein levels were strongly reduced by siRNA mediated knock down
(S9 Fig). EBF1 and EBNA2 binding to chromatin was tested by ChIP followed by quantitative
PCR (ChIP-qPCR) for six selected enhancer loci, three CBF1 independent and three CBF1
dependent (Fig 7) sites, which also bind CBF1 and EBF1 in LCLs. While EBNA2 binding to
CBF1 independent peaks was significantly reduced after EBF1 knock-down, CBF1 dependent
EBNA2 binding was not significantly changed at reduced EBF1 levels. Thus, although EBF1
can bind to CBF1 dependent peaks it does not contribute to EBNA2 recruitment in this
context.
Discussion
EBNA2 can regulate cellular gene expression in CBF1 deficient B cells
Despite the ubiquitous expression of its anchor protein CBF1, EBNA2 is preferentially
recruited to B cell specific enhancers and super enhancers [10, 11, 20, 34, 35]. The underlying
mechanism that recruits EBNA2 specifically to these sites in B cells is still not understood and
hard to study in the constitutive presence of CBF1. Since it was expected and also shown by
other labs that CBF1 knock-down is not compatible with long term proliferation of LCLs [16,
17], we used a CBF1 deficient EBV negative B cell line to study whether EBNA2 can activate
cellular genes and bind to chromatin in the absence of CBF1. This CBF1 deficient B cell line
had been generated by targeted homologous recombination in DG75, a somatic cell line
derived from an EBV negative Burkitt’s lymphoma [36]. The proliferation of DG75 cells is
dot represents one EBNA2 peak. Correlation analyses were performed and Spearman correlation coefficients (rs) were calculated for each pair. A
perfect correlation results in a line (upper left panel) and rs = 1 for EBNA2. Spearman correlation coefficients (rs) were calculated for E2 (1.0),
CBF1 (0.46), PU.1/SPI1 (0.19) and EBF1 (0.4). (E) Genome wide quantitative correlation study of EBNA2, CBF1, PU.1, and EBF1 binding
intensities represented as matrix. The human genome was divided in 100 bp bins and mapped reads per bin were counted. A correlation
coefficient using Spearman correlation was calculated for each TF pair and is displayed and color coded in the matrix.
https://doi.org/10.1371/journal.ppat.1006664.g005
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driven by the reciprocal t (8;14) translocation which hyper-activates c-MYC expression and
which renders proliferation of this cell line CBF1 independent [21].
EBNA2 target gene expression has been intensively studied but due to the omnipresence of
CBF1, CBF1 independent target genes, direct or indirect, have never been discovered [21, 22,
37–46]. Unfortunately, a direct comparison of target gene lists across all studies and biological
systems that have been published would be misleading, since different methodologies, thresh-
olds and time points were applied. In addition, the use of different gene array systems does not
allow the re-analysis of primary data sets as we have done for ChIP-Seq results taken from pub-
lished data sets. Under these circumstances, the absence of evidence does not provide evidence
for absence.
The comparison, however, can be made for selected EBNA2 target genes which were ana-
lyzed under similar conditions. While some target genes were identified in all studies, others
appear specifically in distinct B cell lines as exemplified by the EBNA2 target gene CXCR7
which is induced in LCLs and BL41, a Burkitt’s lymphoma cell line, but not in BJAB, a human
Fig 6. EBNA2 and EBF1 form protein complexes in CBF1 proficient and deficient DG75 B cells. (A) DG75doxHA-E2 CBF1 wt and
CBF1 ko B cells or (B) DG75doxHA-E2WW CBF1 wt B cells were transfected with EBF1 expression plasmids or empty vector controls.
EBNA2 expression was induced by doxycycline (Dox) treatment directly after transfection or cells were left untreated. Total cellular
extracts were harvested after 24 h and subjected to immunoprecipitation (IP) using an EBF specific antibody and then assayed by
Western blot (WB) using EBF and EBNA2 specific antibodies. Total cell lysates (L) represent 1% of the cells used for IP (n = 2, one
representative experiment is shown). (C) DG75 were transfected with EBF1 expression plasmids (+) or empty vector controls (-). Total
cellular extracts were harvested 24 h post transfection, incubated with GST or GST-END domain fusion proteins coupled beads to pull
down associated proteins. Western blot detection was performed with EBF and GST specific antibodies. GAPDH was used as an internal
loading control (n = 2, one representative experiment is displayed).
https://doi.org/10.1371/journal.ppat.1006664.g006
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Fig 7. EBNA2 requires EBF1 to bind to its CBF1 independent binding sites. DG75doxHA-E2 CBF1 wt or
CBF1 ko B cells were transfected with a mixture of scrambled non-targeting siRNAs (siCNTRL) or EBF1
specific siRNAs (siEBF1). 8 h post transfection, EBNA2 transcription was induced. 24 h post transfection,
cells were harvested and analyzed by immunoblots (S9 Fig) and ChIP-qPCR. In the upper panel, EBNA2 (E2)
binding signal and peak tracks as obtained in DG75doxHA-E2 (DG75) as well as EBNA2, CBF1 and EBF1 peak
EBF1, a cofactor of EBNA2
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lymphoblastoid B cell line [22, 46]. These findings suggest that activation of a subset of EBNA2
target genes requires specific cellular factors which, unlike CBF1, are not ubiquitously
expressed. The DG75 cell lines used here express extremely low levels of the cellular transcrip-
tion factors IRF4 and BATF, which are both well expressed in LCLs (S7C Fig) and highly
enriched at LCL unique EBNA2 binding sites (Fig 2D). In addition, chromatin signatures at
enhancer positions that can be bound by EBNA2 are distinct for DG75 and naïve B cells (Fig
2C). Thus, EBNA2 target gene activation is fine-tuned by multiple factors in B cells. We expect
that additional rate limiting transcription factors apart from EBF1 control EBNA2 functions.
A comparative analysis of CBF1 proficient and deficient B cells with distinct transcription fac-
tor signatures will be required to identify these additional factors.
Our genome wide gene expression studies confirm previously described EBNA2 cellular
target genes which are also induced in LCLs like CD21, SLAMF1, RHOH, HEY1 or CCR7 [22]
and in addition identify novel cellular EBNA2 target genes including long non-coding RNAs
and micro RNAs. Notably, EBNA2 also controls a smaller but well defined set of CBF1 inde-
pendent target genes. A selection of targets was validated by qPCR and confirmed the robust
regulation of targets in both cell lines proving a strong biological activity of EBNA2 in CBF1
deficient B cells.
It is important to note that EBNA2 not only activates a set of direct target genes but thereby
initiates a cascade of secondary events, which are included in our target gene lists and in total
reflect EBNA2 functions. CBF1 dependent induced targets were strongly enriched for biologi-
cal processes involved in immunoglobulin receptor binding functions and a broad array of
enzymatic activities. While CBF1 independent EBNA2 induced targets were not significantly
enriched for any biological processes, repressed and CBF1 independent targets could be
assigned to multiple biological processes involving immune responses. Some of these repressed
B cell specific genes like CD79A/mb1, CD79B/B29, VpreB3 have been described previously
[21, 22, 47]. These targets are well characterized EBF1 induced target genes in mice [19, 48–
51] and have been confirmed in human cells [52]. Recently, it has been demonstrated that
EBNA2 promotes the formation of new CBF1 and EBF1 chromatin binding sites [17]. We
speculate that EBNA2 might redirect EBF1 to novel chromatin sites and thereby deplete EBF1
activities required for target gene activation.
EBF1 is a chromatin anchor for EBNA2 at CBF1 independent EBNA2
binding sites
Several lines of evidence support a dynamic model for CBF1/DNA complex formation. Rather
than functioning as a pre-bound DNA anchor, this dynamic model suggests that CBF1 is
recruited to its DNA binding sites when complexed to cellular or viral binding partners. Notch
[53], EBNA2 [17, 44], the EBV viral protein EBNA3C [54] and also RTA [55], the KSHV
derived CBF1 binding protein, all promote CBF1/chromatin complex formation and influence
chromatin site recognition. We propose that additional tissue-specific cellular or viral factors
guide CBF1 associated activator or repressor proteins to functional regulatory elements in the
cell.
Our genome-wide EBNA2 ChIP-Seq studies revealed that EBNA2 can bind to chromatin in
a CBF1 independent manner. We used publicly available information on transcription factor
tracks in LCLs are shown for three (A) CBF1 independent or (B) CBF1 dependent EBNA2 binding sites. ChIP-
qPCR results for EBF (middle panel) and EBNA2 (lower panel) binding to chromatin before and after EBF1
knock down are shown. Data are mean values, whiskers display standard deviations, p-values, based on a
two tailed, paired t-test, are indicated.
https://doi.org/10.1371/journal.ppat.1006664.g007
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occupancy in LCLs or peripheral human B cells to characterize different subpopulations of
EBNA2 binding sites: i) EBNA2 binding sites shared by or unique to either LCLs or DG75 and
ii) CBF1 independent and dependent binding sites. The total number of EBNA2 binding sites
found in DG75 cells was significantly smaller than the number of binding sites found in LCLs,
although EBNA2 was expressed abundantly in DG75 transfectants. Most EBNA2 binding sites
initially identified in DG75 cells were shared with LCLs (S8 Fig). In LCLs, CBF1 independent
binding sites score as strong EBNA2 binding sites (Fig 3D and 3E) and EBF1 is significantly
enriched (Fig 5B and 5C).
In silico transcription factor binding analysis predicted CBF1, EBF1 and MEF2 to be bound
at CBF1 dependent binding sites while CBF1 independent EBNA2 binding sites were predicted
to bind EBF1 only. Thus these latter binding sites might have low affinity for CBF1 suggesting
that EBF1 might be a B cell specific chromatin co-factor for EBNA2, which enhances complex
formation also in CBF1 proficient LCLs and DG75 at sites with low affinity for CBF1. Interest-
ingly, we observed that EBNA2 can enhance EBF1 expression and thus might further support
complex formation (S1 Table).
For our study, we re-analyzed publicly available primary data sets and correlated signal
intensities of transcription factors either at a genome wide level or by focusing on EBNA2
binding sites. These quantitative correlation studies on CBF1, PU.1/SPI1, EBF1, and EBNA2
signal intensities revealed a strong positive correlation of CBF1 and EBF1 to EBNA2 and weak
correlation of CBF1 and EBF1 to each other. Surprisingly, PU.1/SPI1 binding activity corre-
lated with neither EBNA2, nor CBF1 nor EBF1 binding activity (Fig 5D and 5E). A physical
interaction of PU.1/SPI1 and EBNA2 has been described, but was never characterized in detail
[56, 57]. Transient promoter reporter studies had previously suggested that both, PU.1/SPI1
and CBF1 are critical for transactivation of the viral LMP1 promoter by EBNA2 [13, 15, 58].
However, inactivation of the PU.1/SPI1 binding site at the LMP1 promoter in the viral genome
did not grossly change the transformation potential of the viral mutants. LMP1 expression and
proliferation was diminished but not abolished while inactivation of the EBF1 binding site
ablated LMP1 expression [16]. To date, there is no experimental proof indicating that EBNA2
is recruited to chromatin by PU.1/SPI1 [17]. If the pioneer factor PU.1/SPI1 does not serve as
chromatin anchor for EBNA2, it could facilitate the access of transcription factors to com-
pacted chromatin or prevent chromatin silencing at the respective enhancer regions [59].
In order to define the contribution of EBF1 to EBNA2 chromatin binding, EBF1 protein
expression was downregulated by siRNA. These knock down experiments proved that EBNA2
needs EBF1 to bind efficiently to CBF1 independent chromatin sites in both, CBF1 proficient
and deficient cells. In contrast, EBNA2 binding to CBF1 dependent sites was not impaired by
EBF1 siRNA knock down and thus was defined to be EBF1 independent although EBF1 is
present (Fig 7B). EBF1 and EBNA2 binding is consistently weaker in CBF1 deficient compared
to CBF1 proficient DG75 cells (Fig 7). Surprisingly, EBF1 binding is elevated at CBF1 indepen-
dent sites in CBF1 proficient LCLs (Fig 5). Thus, CBF1 might contribute to the assembly of
EBNA2/EBF1 complexes on chromatin, a concept which is consistent with findings of Lu et al.
(16), describing EBF1/CBF1 co-occupied binding sites which are preferentially formed in the
presence of EBNA2.
EBF1 and CBF1 bind to different regions of EBNA2
Here we show that EBNA2 and EBF1 can form complexes in cells and thus provide the first
evidence that EBF1 interacts with a viral protein. Only a few cellular binding partners of EBF1
have been described so far. EBF1 can bind DNA as a homodimer [60], but can further interact
and cooperate with other transcription factors like MEF2C [61], the deoxygenase TET2, an
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enzyme involved in the DNA demethylation process [62], or the histone acetyltransferase CBP
[63]. EBF1 also binds to CNOT3, a subunit of the CCR4-NOT complex [64] which regulates
multiple steps in RNA metabolism including transcription, nuclear RNA export and RNA
decay [65], and thereby also modulates target gene profiles of EBF. In addition, two multi-zinc
finger proteins, ZNF423 and ZNF521, antagonize the biological activity of EBF1 and thereby
might promote tumorigenesis [66]. It should be mentioned that in B cells, with a single excep-
tion (CNOT3), these interactions have been described after expressing at least one binding
partner ectopically or using cross-linking reagents before co-immunoprecipitations have been
performed [61]. Thus, it appears that EBF1 protein-protein interactions are particularly diffi-
cult to detect at endogenous expression levels in B cells. To date we and others have tried and
failed to detect EBNA2/EBF1 complexes expressed at endogenous levels in LCLs while
EBNA2/CBF1 complexes could be readily detected in LCLs [17]. Here we detect EBF1/EBNA2
complexes after overexpression of both binding partners in cells. Importantly, the purified
END domain consisting of 58 amino acids of EBNA2 is sufficient to specifically affinity cap-
ture EBF1 from cellular extracts.
Future studies on purified proteins of both binding partners will reveal whether the interac-
tion of EBNA2 and EBF1 is direct or whether so far unknown factors, proteins or DNA, sup-
port complex formation. If additional cellular factors promote complex formation, they need
to be expressed at very high levels in the cell to efficiently bridge viral and cellular proteins.
In summary, the genetic ablation of CBF1 expression in B cells provides novel valuable
insights into the molecular mechanisms of EBNA2 activity. At this point of our study, we can
define EBNA2 functions in the absence of CBF1. Chromatin conformation capture techniques
performed in DG75 cells will be required to link EBNA2 binding sites to the respective target
genes. Since EBNA2/EBF1 complex formation could be demonstrated in CBF1 proficient and
deficient cells and EBF1 and CBF1 bind to different regions of EBNA2, heterotrimeric com-
plexes might be formed. Whether these complexes activate or repress transcription might
depend on their composition and the chromatin context of enhancer and promoters they bind
to. Any working hypothesis to be tested will have to take into account the dimeric nature of
EBNA2 and EBF1 as well as the fact that CBF1 and EBF1 are co-expressed and their binding
motifs might overlap [67]. Our future studies will need to explore the architecture of these
complexes in order to understand if pre-formed EBNA2/CBF1 complexes can use EBF1 to




pcDNA3 (pCDNA3) and EBF1-myc expression plasmid (pCDNA3.EBF1-5xmyc) were kindly
provided by Mikael Sigvardsson [68]. pCKR74.2 is a Dox (doxycycline) inducible HA- (hae-
magglutinin) tagged EBNA2 expression plasmid (pCKR74.2) based on pRTR [69, 70].
Cell lines and cell culture conditions
The cells were maintained as suspension cultures in RPMI 1640 medium (Gibco Life Technol-
ogies) supplemented with 10% FCS (fetal calf serum, Bio&Sell), 4 mM L-Glutamine and 1 x
penicillin/streptomycin (Gibco Life Technologies). 721 is an EBV positive LCL cell line [71].
The DG75 ko cell line (SM224.9), DG75ER/EBNA2 CBF1 wt and ko cells (SM295 and SM296)
have been described before [21, 22]. The ER/EBNA2 (estrogen receptor hormone binding
domain EBNA2) fusion protein was activated by cultivating the cells in cell culture medium
supplemented with 1 μM ß-estradiol. The DG75doxHA-E2/CBF1 wt (CKR128-34) and the
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DG75doxHA-E2/CBF1 ko (CKR178-10) cell lines carry the Dox inducible HA-EBNA2 expres-
sion plasmid (pCKR74.2). DG75doxHA-E2WW/CBF1 wt (CKR436) expresses a Dox inducible
HA-EBNA2 WW325FF mutant (pCKR421). They were cultivated in 1 μg/ml puromycin con-
taining media. EBNA2 expression was induced by doxycycline treatment (1μg/ml).
Genome wide expression analysis by application of the Human Gene 2.0
ST array (Affymetrix) and relative quantification of transcripts by real-
time RT-PCR
Total RNA was extracted from 1x107 cells induced for 24 h with 1 μM ß-estradiol using the
Qiagen RNeasy Mini Kit. Expression analysis starting from 100 ng of total cellular RNA was
performed using the Ambion WT Expression Kit (Applied Biosystems) and subsequently the
GeneChip WT Terminal Labeling and Hybridization Kit (Affymetrix) followed by the Gene-
Chip Human Gene 2.0 ST array (Affymetrix) according to the manufacturer’s protocol. All
affymetrix CEL files have been processed in Bioconductor/R using robust multiarray average
(RMA) for normalization and summarization and limma for differential expression and signif-
icance. Quality has been checked using the array QualityMetrics package. Additional filtering
based on the fold change between the two conditions was applied with different stringency,
individually described in the legend of the tables and figures. Analyzation and visualization of
the Microarray was performed using Genesis, available at http://genome.tugraz.at. Quantita-
tive RT-PCR analysis was performed as described previously [72]. Primers used for RT-qPCR
were designed applying Primer3 software (http://primer3.ut.ee/) and selection of mature tran-
scripts was ensured by amplification across exon-exon junctions. Primers used for quantitative
RT-PCR are summarized in S3 Table. All data were normalized for the relative abundance of
the Actin B transcript.
Gene ontology analysis
GOrilla is a tool to identify and visualize enriched GO terms in ranked lists of genes (http://
cbl-gorilla.cs.technion.ac.il/) [73]. Enrichment is defined as E = (b/n) / (B/N), with N = the
total number of genes, B = the total number of genes associated with a specific GO term,
n = the number of genes in the top of the user’s input list and b = the number of genes in the
intersection. The threshold for n is selected by GOrilla by maximizing E and statistical signifi-
cance is computed taking into account the multiple hypothesis tests arising due to the
maximization.
All GO terms for which B< 10 were ignored. GO terms with a q-value (FDR) 10−4 were
selected and ranked for their enrichment score given by GOrilla.
As induction and repression was stronger in DG75ER/EBNA2 CBF1 wt cells than in CBF1
ko cells, principal component analysis (PCA) was used to identify genes regulated on average
or differentially between wt and ko (S6 Fig). PCA was performed for all genes significantly reg-
ulated in CBF1 wt or ko cells (limma q< 0.01). The first principal component corresponded
to average regulation while the second principal component represented CBF1 dependence.
Genes were first ranked according to the first principal component, i.e. top entries corre-
sponded to genes that were induced on average in CBF1 wt and ko cells. This was repeated
after reversing the list to analyze genes repressed on average. Furthermore, from each of these
two lists, the top 2000 genes were selected and both were ranked according to the second prin-
cipal component. Both lists were additionally reversed. Therefore, in these four additional lists,
genes that are either induced or repressed on average were ranked according to their degree of
CBF1 dependence.
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Immunoprecipitation (IP)
1x107 DG75doxHA-E2/CBF1 wt or ko cells were lysed in 500 μl NP-40 lysis buffer (1% NP-40,
150 mM NaCl, 10 mM Tris-HCL pH 7.4, 1mM EDTA pH 8.0, 3% Glycerol) supplemented with
complete protease inhibitor cocktail (Roche) for 1h (30 min rolling at 4˚C, 30 min on ice). Pre-
cleared protein lysates were used for co-immunoprecipitation by adding 100 μl of hybridoma
supernatant (E2: α-HA R1 3F10; E.Kremmer) or 1 μg of purified antibody (α-EBF Santa Cruz
Biotechnology, sc-137065) at 4˚C under rotation overnight. Subsequently, 50 μl of 50% suspen-
sion of pre-blocked, equilibrated protein G-coupled Sepharose beads (GE Healthcare) were
added to the lysates and incubated for 2h at 4˚C under rotation. Immunoprecipitates were
washed 5 times with NP-40 lysis buffer, Laemmli buffer was added to the beads, and the samples
were boiled, submitted to electrophoresis by SDS-PAGE and analyzed by immunoblotting.
Immunoblotting (Western blot)
5x 106 cells were lysed in 200 μl NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 10 mM Tris-
HCL pH 7.4, 1mM EDTA pH 8.0, 3% Glycerol) for 2 h on ice. 30 μg of total cell lysate were
submitted to SDS-PAGE under reducing conditions. Immunoblotting was performed on poly-
vinylidene difluoride (PVDF) membranes. Western blots were probed with the following pri-
mary antibodies: rat α-EBNA2 (R3; IgG2A; E. Kremmer), rat α-CBF1 (RBP-J 7A11, E.
Kremmer), rat α-GST (GST 6G9, IgG2A, E. Kremmer), mouse α-EBF (Santa Cruz Biotechnol-
ogy, sc-137065), goat α-BATF (B-ATF H-19, Santa Cruz Biotechnology, sc-15280), rabbit
αIRF4 (IRF4H-140), and-GAPDH (EMD Millipore MAB374). HRP-coupled secondary anti-
bodies (Santa Cruz Biotechnology) and an ECL kit (GE Healthcare) were used for visualiza-
tion. For subsequent quantification of protein levels, exposed films were scanned in
transmission mode and protein band intensities were determined by densitometry using Ima-
geJ software (http://rsbweb.nih.gov/ij/) [74].
Transfection
5x 106 DG75 cells were transfected by electroporation at 250 V and 950 μF in 250 μl reduced
serum media (Opti-MEM, Gibco Life Technologies; without supplements) using 0.4 cm-elec-
trode-gap cuvettes (Bio-Rad) and the Bio-Rad Gene Pulser.
siRNA knockdown in DG75 cells
5x 106 cells were transfected with 100 pmol control siRNA-A or EBF1 siRNA (both Santa Cruz
Biotechnology, sc-37007 and sc-10695) by electroporation. 24 h after transfection, 1x 107
induced, siRNA treated cells were harvested for chromatin isolation and 5x106 cells for protein
isolation.
Chromatin immunoprecipitation
This ChIP protocol is based on reference (59) with minor modifications as indicated below. In
brief, 2x 107 DG75doxHA-E2 cells were harvested and washed twice in ice cold PBS, resuspended
in 20 ml RPMI 1640 (Gibco Life Technologies) and formaldehyde (1% final) was added for
cross-linking. The reaction was stopped by addition of glycine (125 mM final) after 7 min and
gentle shaking for 5 min at RT. Cells were pelleted and washed twice in ice cold PBS. Nuclei
were isolated by washing the cells 3x with 10 ml of ice cold Lysis Buffer (10 mM Tris-HCl, pH
7.5, 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40, 1x proteinase inhibitor cocktail (PIC, Roche))
and subsequent centrifugation (300 g for 10 min at 4˚C). Nuclei were resuspended in 1 ml
Sonication Buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, pH 8.0, 0.5% SDS, 1x PIC) and
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incubated on ice for 10 min. Chromatin was sheared to an average size of 200–300 bp by four
rounds of sonication for 10 min (30 sec pulse, 30 sec pause) using a Bioruptor device (Biogen-
ode). Cell debris was separated by centrifugation at maximum speed for 10 min at 4˚C and
chromatin containing supernatants were stored at -80˚C or directly used for IP. To prepare
input DNA, 25 μl aliquots (1/10 of the amount used per IP) were saved at -80˚C. For IPs 250 μl
chromatin (equals 5x 106 cells) were diluted 1:4 with IP Dilution Buffer (12.5 mM Tri-HCl, pH
8.0, 212.5 mM NaCl, 1.25% Triton X-100, 1 x PIC) and incubated with 100 μl of hybridoma
supernatant on a rotating platform at 4˚C overnight. A combination of EBNA2 and HA-tag
specific antibodies ( α-E2 R3 (rat IgG2a, α-E2 1E6 (rat IgG2a), and α-HA R1-3F10 (rat
IgG1)) was used to precipitate EBNA2 and an isotype-matched unspecific antibody mixture (
α- GST 6G9 (rat IgG2a) and α-CD23 Dog-CD3 (rat IgG1) both by E. Kremmer) was used as
isotype control. The EBF antibody (C-8) (sc-137065, Santa Cruz Biotechnology) was used to
precipitate EBF1 and an antibody specific for ovalbumin (M-Ova 3D2, E. Kremmer) was used
as an isotype control. Protein G sepharose (GE Healthcare) was equilibrated with IP Dilution
Buffer, added to the lysate and incubated at 4˚C for 4 h with constant rotation. Beads were
extensively washed with: 2x Wash Buffer I (20 mM Tris-HCl, pH 8.0, 2 mM EDTA, pH 8.0,
1% Triton X-100, 150 mM NaCl, 0.1% SDS, 1x PIC), 1x Wash Buffer II (20 mM Tris-HCl, pH
8.0, 2 mM EDTA, pH 8.0, 1% Triton X-100, 500 mM NaCl, 0.1% SDS, 1x PIC), 1x Wash Buffer
III (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 250 mM LiCl, 1% NP-40, 1% sodium
deoxycholate, 1x PIC) for 5 min under rotation, and 2x with TE (10 mM Tris-HCl, pH 8.0, 1
mM EDTA, pH 8.0) for 1 min. Protein-DNA complexes were eluted with 2x 150 μl Elution
Buffer (25 mM Tris-HCl, pH 7.5, 10 mM EDTA, pH 8.0, 1% SDS) at 65˚C for 15 min. Input
samples were adjusted to 300 μl with Elution Buffer. Eluates and input samples were incubated
with Proteinase K (1.5 μg/μl final, Roche) for 1 h at 42˚C. Cross-linking was reversed by incu-
bation at 65˚C overnight. DNA was recovered using QIAquick PCR purification kit (Qiagen).
The EBNA2 specific ChIP in LCL was performed as described above with the following
modifications: Protein-protein interactions were fixated by adding disuccinimidyl glutarate
(DSG, Pierce #20593, 2 mM final, using freshly prepared 0.5 M stock solution in DMSO) for
23 min at RT and prior to formaldehyde (1% final) cross-link for additional 7 min. Sonication
Buffer was composed of 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, pH 8.0, 0.5% SDS, 0.5% Tri-
ton X-100, 0.05% sodium deoxycholate, and 1x PIC. IP Dilution Buffer was composed of 12.5
mM Tri-HCl, pH 8.0, 187.5 mM NaCl, 1.25 mM EDTA, pH 8.0, 1.125% Triton X-100, and 1 x
PIC. For EBNA2 specific IP 50 μl of α-E2 R3 (rat IgG2a) and 50 μl α-E2 1E6 (rat IgG2a)
hybridoma supernatant were applied and the same volume of isotype-matched nonspecific
antibody (α- GST 6G9 (rat IgG2a) E. Kremmer) was used as negative control.
Whole-genome chromatin immunoprecipitation DNA sequencing (ChIP-
seq)
For sequencing purposes DNA concentration was measured using the Qubit dsDNA HS
Assay Kit (Thermo Fisher). A maximum of 100 ng ChIP or input derived DNA were used for
library preparation (NEBNext Ultra DNA Library Prep Kit for Illumina) and subsequently
subjected to deep sequencing using a HiSeq 1500 device (Illumina).
Chromatin immunoprecipitation quantitative polymerase chain reaction
(ChIP-qPCR)
The amount of recovered DNA in input samples and after IP with specific antibody or an
unspecific isotype-matched IgG control was quantified by qPCR using primers listed in S3
Table.
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qPCR was performed using LightCycler 480 SYBR Green I Master (Roche) on a LightCycler
480 II instrument (Roche) as described previously [72]. 2 technical replicates were analyzed
for each biological replicate. Amplification was always conducted at 63˚C. To account for dif-
ferences in amplification efficiencies a standard curve was generated for each primer pair
using serial dilutions of sheared DNA (input) as template. DNA quantities detected in input
samples were adjusted to the amount of chromatin used per IP by multiplication with 20. Val-
ues obtained from IP samples with unspecific IgG control were subtracted from the DNA
amounts recovered by IP with specific antibody. The percent of input was calculated as (DNA
from specific IP corrected for IgG control background/ DNA input) x 100. To validate the
ChIP, qPCR at a known (ChIP-Seq) positive locus was performed. To compromise divergent
EBNA2 inducibility in wildtype and knockout cells, the percent input was calculated relative to
a known negative locus (ChIP-Seq; percent input at tested locus/percent input of known nega-
tive locus). To display the change in binding, the mean relative input of the wildtype cells
treated with control siRNA was set to one. A paired t-test was performed to assess significance
of differences of means.
Expression and purification of GST fusion proteins
Expression plasmids were transformed into E.coli strain BL21. Bacteria were cultured in 400
ml of LB medium containing antibiotics at 37˚C until an OD of 0.5–0.7 was reached. Expres-
sion of proteins was induced with 1 mM IPTG for 3 h at 30˚C. After induction, bacteria were
suspended in 20 ml ice cold binding buffer (25 mM HEPES, pH 7.6, 0.1 mM EDTA, pH 8, 12.5
mM MgCl2, 10% Glycerol, 0.1% NP-40, 100 mM KCl, 1 mM PMSF, 1 mM DTT, 1 mM PMSF)
and lysed by sonication. Lysates were cleared by centrifugation at 48,000 x g at 4˚C for 20 min.
Glutathione Sepharose 4B beads (GE Healthcare) were washed and resuspended in binding
buffer to prepare a 50% slurry. To coat the beads with GST or GST fusion protein, 100 μl of the
50% slurry were incubated with the 20 ml of cleared lysates for 1 hat 4˚C and washed 3 times
with 20 ml binding buffer.
GST pull down assay
1x107 DG75 cells were transfected with EBF1 expression plasmids or empty vector controls. 24
h after transfection, cells were harvested and lysed in 500 μl lysis buffer (50 mM HEPES, pH
7.6, 5 mM EDTA, pH 8, 150 mM NaCl, 0.1% NP-40, 1 mM PMSF) followed by sonication.
Cell lysates were centrifuged for 15 min at 16,000x g, 4˚C, and the protein concentration was
measured by Bradford assay. To pull down EBF1, the supernatants were incubated with the
GST or GST fusion protein coated beads for 3 hat 4˚C. Subsequently, beads were washed 5
times with binding buffer and protein complexes were dissolved in 2x La¨mmli buffer (4% SDS,
20% Glycerol, 120 mM Tris/HCl, pH 6.8, 5% β-Mercaptoethanol, Bromphenol-blue). Samples
were analyzed by SDS-PAGE and Western Blot.
Bioinformatics
All bioinformatic analyses of ChIP-Seq data were conducted by using the galaxy bioinformat-
ics platform [75] hosted and maintained by the Bioinformatics Department of the University
of Freiburg. For all sequenced samples, at least 17 million reads were obtained and biological
duplicates of EBNA2 ChIP and input samples were sequenced. Reads were mapped to the
human genome using Bowtie2 [76]. For all samples, at least 95% of reads were mappable to the
human genome including at least 69% of uniquely mapping reads with one distinct location
(S4 Table). Biological duplicates of mapped reads were merged and subsequently significant
EBNA2 binding sites were identified using MACS2 [77] by normalizing ChIP to input samples
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(S4 Table). In a second step, the peaks were further filtered and “negative peaks” (negative
amplitude, significantly higher read count in the input sample), peaks located at black-listed
regions [78], peaks with a very low enrichment score, and such located on chromosomes not
included in the ENCODE data for GM12878 (e.g. chrY, chrUn) were excluded (S4 Table).
Normalized EBNA2 ChIP signal tracks were generated by subjecting duplicate-merged ChIP
and input read files to bamCompare of the deepTool package [79] and normalizing ChIP to
input samples by subtraction as well as normalizing to fragments (reads) per kb per million
(RPKM) to account for genome coverage. Mean signal intensities at specific peak sets were cal-
culated using computeMatrix of the deepTools package. This workflow for transcription factor
peak calling and signal track generation was applied to all ChIP-seq data sets analyzed in this
manuscript. A separate workflow for the analysis of histone modification ChIP-seq data was
generated to account for the typical broader signal distribution and applied to all such data
sets analyzed in this study. Data provided by public resources were reanalyzed using the same
pipeline as described above and references are listed in S5 Table. The details of all analyses
steps are captured in a Galaxy workflow which can be downloaded at github (https://github.
com/bgruening/galaxytools/tree/master/workflows/peak_calling) and re-run and analyzed in
Galaxy. Cluster analysis was performed using the k-means algorithm tool (numbers of clusters
expected = 12, max. iterations = 50) provided by Genesis (release 1.7.7), available at http://
genome.tugraz.at. Genesis was also used to generate heatmaps [80].
Flow cytometry
Inducibility of EBNA2 expression in DG75doxHA-E2/CBF1 wt and ko cell lines was evaluated by
monitoring the expression of the eGFP surrogate marker of pCKR74.2. Cells were induced for
16 h or 24 h with doxycycline, washed and fixed with 0.5% PFA in PBS. For quantification of
induced cells, the FACSCalibur system (BD Biosciences) and CellQuest Pro software (BD Bio-
sciences) were applied.
Supporting information
S1 Fig. Control panels documenting estrogen responses in ER/EBNA2 expressing DG75
cells compared to estrogen treated untransfected parental cell lines. (A) DG75 parental cells
(DG75 CBF1 wt), CBF1 deficient (DG75 CBF1 ko), ER/EBNA2 expressing (DG75ER/EBNA2
CBF1 wt), and CBF1 deficient ER/EBNA2 expressing DG75 cells (DG75ER/EBNA2 CBF1 ko)
were treated with estrogen for 24 h or were left untreated. Total cellular RNA was isolated and
submitted to gene expression analysis using the Human Gene 2.0 ST array. All probe sets rep-
resent single transcripts. For each condition 3 biological replicates were examined. Each verti-
cal column in the heatmap represents the results obtained from a single microarray.
Horizontal rows represent data obtained for a particular probe set across all cell lines and con-
ditions after normalization of expression values on a scale ranging from -2.0 to 2.0 for each
probe set. Expression levels of 950 transcripts which change expression levels at least 2-fold
(p 0.05) in response to estrogen in DG75 ER/EBNA2 cells are displayed. The relative high,
medium and low expression values are represented by red, white and blue, respectively. Verti-
cal columns are ranked according to fold changes in ER/EBNA2 expressing DG75 from high-
est induction on top to highest repression levels at the bottom. (B) RNA expression levels of a
panel of previously described estrogen responsive target genes in DG75 cells after estrogen
treatment (RMA = robust multi array average). (C) RNA expression level of previously defined
EBNA2 target genes in DG75 ER/EBNA2 cells after estrogen induction.
(TIF)
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S2 Fig. Based on the expression level changes of 950 transcripts which are regulated in
DG75ER/EBNA2 CBF1 wt at least 2-fold (p 0.05) and expression levels of the same tran-
scripts in DG75ER/EBNA2 CBF1 ko cells, 12 clusters of transcripts were defined. Number of
transcripts contained in each cluster is indicated on the left. Unique ID and Gene Name are
listed in S2 Table.
(TIF)
S3 Fig. Heatmap representing the 132 transcripts regulated at least 2-fold (p 0.001) by
EBNA2 in CBF1 deficient DG75ER/EBNA2 cells. Total cellular RNA was isolated and submit-
ted to gene expression analysis using the Human Gene 2.0 ST array. All probe sets represent
single transcripts. For each condition 3 biological replicates were examined. Each vertical col-
umn represents the results obtained by a single microarray. Horizontal rows represent data
obtained for a particular probe set across all cell lines and conditions on a scale ranging from
-2.0 to 2.0 for each probe set. The relative high, medium and low expression values are repre-
sented by red, white, and blue color, respectively. Vertical columns are ranked according to
fold changes in ER/EBNA2 expressing DG75 CBF1 ko from highest induction level on top to
highest repression levels at the bottom. The transcript cluster ID and the assigned genes/tran-
scripts are indicated. Note that not more than five assigned genes are listed (). If no assign-
ment was available the chromosomal position is indicated ().
(TIF)
S4 Fig. Validation of gene array hybridization results by quantitative RT-PCR. (A) Relative
transcript levels of EBNA2 target genes were quantified from total RNA samples of the indi-
cated cell lines by RT-qPCR. All results were normalized to actin B transcript levels. (B) For
comparison the expression levels measured by gene array hybridization are shown in parallel.
(TIF)
S5 Fig. Heatmap showing microRNAs regulated at least 1.5-fold (p 0.05) by EBNA2 in
DG75ER/EBNA2 CBF1 wt cells (for all details see S1 Fig).
(TIF)
S6 Fig. Identification of individual target gene subsets based on principle component anal-
ysis. Since on average target gene expression changes in CBF1 positive cells were stronger than
in CBF1 negative cells, principle component analysis on EBNA2 regulated genes was used to
identify specific subpopulations: The first principle component (green arrow) describes the
upregulation of genes in both cell lines, the second principle component (red arrow) describes
the degree of CBF1 dependence. The scatter blots depict all genes (A) or the top 2000 (B)
induced/repressed genes which are regulated in at least one cell line.
(TIF)
S7 Fig. Doxycycline inducible HA-EBNA2 expression in CBF1 proficient or deficient
DG75 B cells. (A) pRTRdoxHA-E2 vector used to generate stable DG75 cell lines. The coding
sequence for EBNA2 fused to a N-terminal HA-tag (HA-E2), plus a preceding intron of the
beta-globin gene for enhanced expression, was cloned into the pRTR vector [69, 70] using SfiI
restriction sites. The bidirectional promoter simultaneously drives the expression of
HA-EBNA2 and the bicistronic reporter construct consisting of a truncated nerve growth fac-
tor receptor gene (tNGFR) and enhanced green fluorescent protein (eGFP) gene upon doxycy-
cline induction. (B) Expression of HA-EBNA2 was induced with 1 μg/ml doxycycline (Dox)
for 24 h and monitored by quantifying eGFP expression via flow cytometry and scored at least
89% with a maximum of 5% difference between DG75 CBF1 wt and ko cells. Data from one
representative experiment (n = 3) and percentages of induced cells are shown. (C) Western
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Blot analysis confirming the expression of HA-EBNA2 in DG75doxHA-E2 cell lines 24 h post
induction with 1 μg/ml Dox. 721 is an LCL cell line used as positive control for all western
blots. The absence of CBF1 expression in the DG75doxHA-E2 CBF1 ko cell line is confirmed.
EBF1, IRF4, BATF, and PU.1/SPI1 are shown for comparison. GAPDH serves as loading con-
trol. For all blots 30μg protein lysate was used for all lanes with a single exception: For EBNA2
blots 3 μg DG75 lysates and 30μg 721 lysate were used in order to take the 5–10 fold higher
EBNA2 expression of DG75 into consideration.
(TIF)
S8 Fig. Intersection of EBNA2 binding sites identified in LCLs, DG75doxHA-E2 CBF1 wt
or ko. The table lists (lower part) the called peaks and the fraction of peaks which also score in
LCL EBNA2.
(TIF)
S9 Fig. Validation of efficient EBF1 knockdown by Western blot analysis. DG75doxHA-E2
CBF1 wt or CBF1 ko B cells were transfected with a mixture of scrambled non-targeting siR-
NAs (siCNTRL) or EBF1 specific siRNAs (siEBF1). 8 h post transfection, EBNA2 transcription
was induced. 24 h post transfection, cells were harvested and analyzed by immunoblots and
ChIP-qPCR. (A) Representative immunoblots showing expression levels of EBNA2, EBF1,
CBF1, and GAPDH before and after knockdown (n = 3). EBF1 negative Jurkat cell lysate
served as a negative control. (B) Protein band intensities were quantified by densitometry. The
change of EBF1 protein expression in siRNA (siEBF1) treated compared to non-treated cells
(CNTRL) is significant according to paired t-test when indicated.
(TIF)
S1 Table. Gene array (Human Gene 2.0).
(XLSX)
S2 Table. Gene list k-means clustering (cluster 1–12).
(XLSX)
S3 Table. Primer qPCR.
(PDF)
S4 Table. Summary ChIP-seq results.
(PDF)
S5 Table. Public resources used for this study.
(PDF)
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